Phase 3 Randomized, Double-blind, Controlled Study of ICT-107 in Glioblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02546102
Recruitment Status : Suspended (Company at this time unable to secure sufficient financial resources to complete)
First Posted : September 10, 2015
Last Update Posted : June 23, 2017
Novella Clinical
Information provided by (Responsible Party):
ImmunoCellular Therapeutics, Ltd.